Rothschild Investment LLC Decreases Position in Kenvue Inc. $KVUE

Rothschild Investment LLC trimmed its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 79.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 59,832 shares of the company’s stock after selling 233,469 shares during the quarter. Rothschild Investment LLC’s holdings in Kenvue were worth $1,252,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in KVUE. Vanguard Group Inc. boosted its holdings in Kenvue by 4.9% in the first quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company’s stock worth $5,494,882,000 after acquiring an additional 10,600,682 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Kenvue by 1.2% in the 2nd quarter. Geode Capital Management LLC now owns 49,001,887 shares of the company’s stock valued at $1,021,267,000 after purchasing an additional 604,953 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Kenvue by 2.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 25,606,238 shares of the company’s stock valued at $613,882,000 after purchasing an additional 633,461 shares during the last quarter. Boston Partners boosted its stake in Kenvue by 7.4% in the 1st quarter. Boston Partners now owns 25,346,453 shares of the company’s stock worth $606,920,000 after purchasing an additional 1,750,490 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in Kenvue by 11.6% during the 1st quarter. JPMorgan Chase & Co. now owns 24,912,226 shares of the company’s stock worth $597,395,000 after purchasing an additional 2,597,920 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on KVUE shares. Bank of America decreased their price target on shares of Kenvue from $25.00 to $21.00 and set a “buy” rating for the company in a report on Wednesday, October 8th. Barclays upped their target price on Kenvue from $17.00 to $18.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. UBS Group lowered their price target on Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a research report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft set a $18.00 price target on Kenvue in a research note on Friday, October 24th. Finally, Johnson Rice restated a “neutral” rating on shares of Kenvue in a research note on Tuesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $20.23.

Kenvue Stock Down 2.3%

Shares of KVUE opened at $16.27 on Tuesday. The company has a market capitalization of $31.17 billion, a price-to-earnings ratio of 21.70, a PEG ratio of 2.43 and a beta of 0.71. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $25.17. The stock’s 50-day moving average price is $16.37 and its 200-day moving average price is $19.98. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The company had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.83 billion. During the same period last year, the business earned $0.28 earnings per share. Kenvue’s quarterly revenue was down 3.5% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, sell-side analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th will be issued a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 5.1%. The ex-dividend date of this dividend is Wednesday, November 12th. Kenvue’s payout ratio is 110.67%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.